Varicella zoster vaccine (live/attenuated)

Identification

Brand Names
Proquad, Varivax, Zostavax
Generic Name
Varicella zoster vaccine (live/attenuated)
DrugBank Accession Number
DB10318
Background

Live attenuated zoster vaccine is available as two products: Zostavax for the prevention of shingles in immunocompetent people over the age of 50, and Varivax for the prevention of chickenpox in individuals 12 months of age and older. While the two vaccines contain the same immunological components and provide protection against the same virus, Zostavax contains a higher dose and is used in older adults to prevent the development of shingles and post-herpetic neuralgia.

First approved in May 2006 by the Food and Drug Administration, Zostavax was the first vaccine available for the prevention of shingles. Since October 2017, however, it has been replaced as first line therapy by Shingrix (Varicella zoster vaccine (recombinant)), a more effective and longer lasting vaccine3. Both Varivax and Zostavax are composed of a lyophilized preparation of live, attenuated Oka/Merck strain of varicella-zoster virus.

Varicella Zoster Virus (VZV) is the virus that commonly causes Chickenpox (also known as Varicella) in childhood 4. Following initial infection of VZV and resolution of Chickenpox as a child, VZV then lies dormant within the dorsal root ganglion of the central nervous sytem. Decades later, when the body's immune system weakens with age, VZV is able to reactivate and descend through the nerve cells to the surface of the skin where it causes a painful blistering rash, known as shingles (or Herpes Zoster). Risk factors for developing shingles include old age, with rates increasing substantially in person's over the age of 50, low immune function or immunosuppression, psychological stress, and diabetes. Person's living with HIV or cancer, those taking immunosuppressants, and transplant recipients are particularly at risk 2.

One of the most common complications associated with shingles is the development of Post-Herpetic Neuralgia (PHN), a persistant severe nerve pain that develops as a result of chronic pain from shingles lesions. PHN can last for days, months, or even years following resolution of shingles. Other complications also include bacterial infection, spread of the shingles rash to the eye (herpes zoster ophthalmicus) or ear, nerve palsies, or spread of VZV to non-immune persons via contact with varicella lesions.

There are numerous advantages to using Shingrix over Zostavax. Clinical trials for Shingrix have shown greater than 90% efficacy in adults aged 50 and older, with 89% efficacy in preventing postherpetic neuralgia in patients 70 years and older and 91% efficacy in patients 50-70 years of age. This is a significant improvement over its predecessor, Zostavax, which reduces the risk of shingles by only 51% and the risk of post-herpetic neuralgia by 67% 1. Efficacy of Zostavax also wanes over time, with protection against shingles and PHN lasting only around 5 years. Efficacy for prevention of shingles is highest in patients 60-69 years old and decreases with increasing age. Furthermore, because Shingrix is an inactivated vaccine it can also be used to prevent shingles and PHN in individuals with suppressed immune systems, who are already at increased risk of developing shingles, while Zostavax, a live attenuated vaccine, is contraindicated.

Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Attenuated
Synonyms
  • Chickenpox vaccine
  • Human herpesvirus 3 live (attenuated) antigen
  • Varicella vaccine
  • Varicella virus vaccine live (oka-merck) strain
  • Varicella zoster live (attenuated) antigen
  • Varicella zoster live(attenuated) antigen
  • Varicella-zoster virus (live, attenuated)
  • Varicella-zoster virus strain oka/merck live (attenuated) antigen
  • Varicella-zoster virus strain oka/merck live antigen

Pharmacology

Indication

Zostavax vaccine is indicated for the prevention of herpes zoster (shingles) in immunocompetent adults aged 50 years and older.

Varivax vaccine is indicated for active immunization for the prevention of varicella in individuals 12 months of age and older.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Zostavax provides protection against Herpes Zoster reactivation by eliciting an immune response to Varicella Zoster Virus (VZV).

Varivax provides protection against chickenpox by eliciting both cell-mediated and humoral immune responses to varicella-zoster virus.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirThe therapeutic efficacy of Varicella zoster vaccine (live/attenuated) can be decreased when used in combination with Abacavir.
AbataceptThe risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Abatacept.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Varicella zoster vaccine (live/attenuated).
AcyclovirThe therapeutic efficacy of Varicella zoster vaccine (live/attenuated) can be decreased when used in combination with Acyclovir.
AdalimumabThe risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Adalimumab.
Adefovir dipivoxilThe therapeutic efficacy of Varicella zoster vaccine (live/attenuated) can be decreased when used in combination with Adefovir dipivoxil.
AldesleukinThe risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Aldesleukin.
AlefaceptThe risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Alefacept.
AlemtuzumabThe risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Alemtuzumab.
AltretamineThe risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Altretamine.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
VarivaxInjection, powder, lyophilized, for suspension1350 [PFU]/0.5mLSubcutaneousMerck Sharp & Dohme Corp.1995-03-17Not applicableUS flag
VarivaxInjection, powder, lyophilized, for suspension1350 [PFU]/0.5mLSubcutaneousMerck Sharp & Dohme Corp.1995-03-17Not applicableUS flag
Varivax IIIPowder, for solution1350 PFU/0.5mLSubcutaneousMerck Ltd.2002-12-02Not applicableCanada flag
ZostavaxInjection, powder, for suspension194000 PFU/0.65mlSubcutaneousMsd Vaccins2016-09-08Not applicableEU flag
ZostavaxInjection194000 PFU/0.65mlSubcutaneousMsd Vaccins2016-09-08Not applicableEU flag
ZostavaxInjection194000 PFU/0.65mlSubcutaneousMsd Vaccins2016-09-08Not applicableEU flag
ZostavaxInjection194000 PFU/0.65mlSubcutaneousMsd Vaccins2016-09-08Not applicableEU flag
ZostavaxInjection, powder, lyophilized, for suspension19400 [PFU]/0.65mLSubcutaneousMerck Sharp & Dohme Corp.2006-05-25Not applicableUS flag
ZostavaxInjection194000 PFU/0.65mlSubcutaneousMsd Vaccins2016-09-08Not applicableEU flag
ZostavaxInjection194000 PFU/0.65mlSubcutaneousMsd Vaccins2016-09-08Not applicableEU flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
PRIORIX-TETRAVaricella zoster vaccine (live/attenuated) (1995 PFU/0.5ml) + Measles virus vaccine live attenuated (1000 CCID_50/0.5ml) + Mumps virus strain B level jeryl lynn live antigen (25119 CCID_50/0.5ml) + Rubella virus vaccine (1000 CCID_50/0.5ml)Injectionบริษัท แกล็กโซสมิทไคล์น (ประเทศไทย) จำกัด2014-02-27Not applicableThailand flag
Priorix-TetraVaricella zoster vaccine (live/attenuated) (1995 PFU) + Measles virus vaccine live attenuated (1000 CCID50) + Mumps virus strain B level jeryl lynn live antigen (25119 CCID50) + Rubella virus vaccine (1000 CCID50)Injection, powder, lyophilized, for solutionIntramuscular; SubcutaneousGLAXOSMITHKLINE PTE LTD2009-04-03Not applicable
PRIORIX-TETRA 0.5 ML SC ENJEKSIYON IÇIN LIYOFILIZE TOZ IÇEREN FLAKON VE ÇÖZÜCÜ IÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 DOZ İĞNELİVaricella zoster vaccine (live/attenuated) (10 PFU) + Measles virus vaccine live attenuated (10 CCID) + Mumps virus strain B level jeryl lynn live antigen (10 CCID) + Rubella virus vaccine (10 CCID)Injection, powder, lyophilized, for solutionSubcutaneousGLAXOSMİTHKLİNE İLAÇLARI SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
PRIORIX-TETRA 0.5 ML SC ENJEKSIYON IÇIN LIYOFILIZE TOZ IÇEREN FLAKON VE ÇÖZÜCÜ IÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 DOZ İĞNESİZVaricella zoster vaccine (live/attenuated) (10 PFU) + Measles virus vaccine live attenuated (10 CCID) + Mumps virus strain B level jeryl lynn live antigen (10 CCID) + Rubella virus vaccine (10 CCID)Injection, powder, lyophilized, for solutionSubcutaneousGLAXOSMİTHKLİNE İLAÇLARI SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
PRIORIX-TETRA 0.5 ML SC ENJEKSIYON IÇIN LIYOFILIZE TOZ IÇEREN FLAKON VE ÇÖZÜCÜ IÇEREN KULLANIMA HAZIR ENJEKTÖR, 10X1 DOZ İĞNELİVaricella zoster vaccine (live/attenuated) (10 PFU) + Measles virus vaccine live attenuated (10 CCID) + Mumps virus strain B level jeryl lynn live antigen (10 CCID) + Rubella virus vaccine (10 CCID)Injection, powder, lyophilized, for solutionSubcutaneousGLAXOSMİTHKLİNE İLAÇLARI SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
PRIORIX-TETRA 0.5 ML SC ENJEKSIYON IÇIN LIYOFILIZE TOZ IÇEREN FLAKON VE ÇÖZÜCÜ IÇEREN KULLANIMA HAZIR ENJEKTÖR, 10X1 DOZ İĞNESİZVaricella zoster vaccine (live/attenuated) (10 PFU) + Measles virus vaccine live attenuated (10 CCID) + Mumps virus strain B level jeryl lynn live antigen (10 CCID) + Rubella virus vaccine (10 CCID)Injection, powder, lyophilized, for solutionSubcutaneousGLAXOSMİTHKLİNE İLAÇLARI SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
PRIORIX-TETRA 0.5 ML SC ENJEKSIYON IÇIN LIYOFILIZE TOZ IÇEREN FLAKON VE ÇÖZÜCÜ IÇEREN KULLANIMA HAZIR ENJEKTÖR, 20X1 DOZ İĞNESİZVaricella zoster vaccine (live/attenuated) (10 PFU) + Measles virus vaccine live attenuated (10 CCID) + Mumps virus strain B level jeryl lynn live antigen (10 CCID) + Rubella virus vaccine (10 CCID)Injection, powder, lyophilized, for solutionSubcutaneousGLAXOSMİTHKLİNE İLAÇLARI SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
PRIORIX-TETRA 0.5 ML SC ENJEKSIYON IÇIN LIYOFILIZE TOZ IÇEREN FLAKON VE ÇÖZÜCÜ IÇEREN KULLANIMA HAZIR ENJEKTÖR, 50X1 DOZ İĞNESİZVaricella zoster vaccine (live/attenuated) (10 PFU) + Measles virus vaccine live attenuated (10 CCID) + Mumps virus strain B level jeryl lynn live antigen (10 CCID) + Rubella virus vaccine (10 CCID)Injection, powder, lyophilized, for solutionSubcutaneousGLAXOSMİTHKLİNE İLAÇLARI SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
ProquadVaricella zoster vaccine (live/attenuated) (0.60 TCID50) + Measles virus vaccine live attenuated (0.477 TCID50) + Mumps virus strain B level jeryl lynn live antigen (0.633 TCID50) + Rubella virus vaccine (0.477 TCID50)Injection, powder, for suspensionIntramuscular; SubcutaneousMsd Vaccins2021-03-18Not applicableEU flag
ProquadVaricella zoster vaccine (live/attenuated) (0.60 TCID50) + Measles virus vaccine live attenuated (0.477 TCID50) + Mumps virus strain B level jeryl lynn live antigen (0.633 TCID50) + Rubella virus vaccine (0.477 TCID50)Injection, powder, for suspensionIntramuscular; SubcutaneousMsd Vaccins2021-03-18Not applicableEU flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
VARILRIX SC ENJEKSIYON ICIN LIYOFILIZE TOZ ICEREN FLAKONVaricella zoster vaccine (live/attenuated) (103 PFU)Injection, powder, lyophilized, for solutionIntramuscularGLAXOSMİTHKLİNE İLAÇLARI SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
GPV39ZGD8C
CAS number
Not Available

References

General References
  1. Bharucha T, Ming D, Breuer J: A critical appraisal of 'Shingrix', a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus. Hum Vaccin Immunother. 2017 Aug 3;13(8):1789-1797. doi: 10.1080/21645515.2017.1317410. Epub 2017 Apr 20. [Article]
  2. CDC - Clinical Overview of Shingles (Herpes Zoster) [Link]
  3. CDC - What Everyone Should Know about Shingles Vaccine [Link]
  4. CDC - About Chickenpox [Link]
PubChem Substance
347910497
RxNav
1292422
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Zoster_vaccine
FDA label
Download (408 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingPreventionCartilage-hair Hypoplasia1
4Active Not RecruitingPreventionHepatitis A / Measles / Varicella1
4Active Not RecruitingPreventionHerpes Zoster1
4CompletedNot AvailableMeasles / Mumps / Rubella / Varicella1
4CompletedBasic ScienceHerpes Zoster (Shingles)1
4CompletedPreventionAcute Respiratory Infections (ARIs) / Flu caused by Influenza1
4CompletedPreventionChickenpox1
4CompletedPreventionChickenpox / Encephalitis, Japanese B1
4CompletedPreventionChickenpox / Hepatitis A / Measles / Mumps / Rubella1
4CompletedPreventionFibrosis / Herpes Zoster1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solutionIntramuscular; Subcutaneous
Injection, powder, for solutionIntramuscular; Subcutaneous
Injection
Injection, powder, lyophilized, for solutionIntramuscular; Subcutaneous1000 CCID50
Injection, powder, lyophilized, for solutionSubcutaneous
Injection, powder, for suspensionIntramuscular; Subcutaneous
Injection, powder, lyophilized, for suspensionSubcutaneous
Injection, powder, lyophilized, for suspensionIntramuscular; Subcutaneous
Injection, powder, lyophilized, for solutionSubcutaneous3 log10 tcid50/0.5mL
Injection, powder, for suspension27400 PFU/0.5mL
PowderSubcutaneous1400 PFU/0.7mL
InjectionSubcutaneous2000 PFU/0.5mL
Injection, powder, for solutionSubcutaneous
Injection, powder, for solutionSubcutaneous2000 unit
Powder, for solutionSubcutaneous
Injection, powder, for suspensionSubcutaneous
Injection, powder, lyophilized, for solutionIntramuscular
Injection, powder, for solutionSubcutaneous2000 PFU
Injection, powder, lyophilized, for suspensionSubcutaneous1350 [PFU]/0.5mL
InjectionSubcutaneous2700 PFU/mL
SuspensionSubcutaneous
Powder, for solutionSubcutaneous1350 PFU/0.5mL
Injection, powder, for suspensionIntramuscular; Subcutaneous
Injection, powder, lyophilized, for suspensionSubcutaneous
PowderSubcutaneous1.35 CFU
InjectionSubcutaneous194000 PFU/0.65ml
Injection, powder, for suspensionSubcutaneous19400 PFU/0.65mL
Injection, powder, for suspensionSubcutaneous194000 PFU/0.65ml
Injection, powder, lyophilized, for suspensionSubcutaneous19400 [PFU]/0.65mL
Injection, suspensionSubcutaneous
Injection, powder, for suspensionSubcutaneous19400 PFU
PowderSubcutaneous1350 PFU/0.5mL
PowderSubcutaneous19400 PFU/0.7mL
Injection, powder, lyophilized, for suspension
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 01, 2015 20:03 / Updated on October 20, 2021 19:48